WO2008129535A1 - Method, apparatus and system for predicting electromechanical dissociation - Google Patents
Method, apparatus and system for predicting electromechanical dissociation Download PDFInfo
- Publication number
- WO2008129535A1 WO2008129535A1 PCT/IL2008/000509 IL2008000509W WO2008129535A1 WO 2008129535 A1 WO2008129535 A1 WO 2008129535A1 IL 2008000509 W IL2008000509 W IL 2008000509W WO 2008129535 A1 WO2008129535 A1 WO 2008129535A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- signal
- radiofrequency
- subject
- heart
- onset
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 119
- 206010058151 Pulseless electrical activity Diseases 0.000 title claims abstract description 75
- 230000017531 blood circulation Effects 0.000 claims abstract description 44
- 230000000694 effects Effects 0.000 claims abstract description 42
- 239000002131 composite material Substances 0.000 claims abstract description 35
- 230000000747 cardiac effect Effects 0.000 claims description 44
- 230000004962 physiological condition Effects 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 9
- 230000033764 rhythmic process Effects 0.000 claims description 9
- 230000004044 response Effects 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 4
- 230000008030 elimination Effects 0.000 claims description 4
- 238000003379 elimination reaction Methods 0.000 claims description 4
- 230000010363 phase shift Effects 0.000 description 20
- 238000012545 processing Methods 0.000 description 12
- 208000010496 Heart Arrest Diseases 0.000 description 11
- 238000010586 diagram Methods 0.000 description 9
- 210000004165 myocardium Anatomy 0.000 description 7
- 230000036982 action potential Effects 0.000 description 5
- 230000000004 hemodynamic effect Effects 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 230000003321 amplification Effects 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000000718 qrs complex Methods 0.000 description 4
- 210000001013 sinoatrial node Anatomy 0.000 description 4
- 238000012935 Averaging Methods 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 208000010444 Acidosis Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003990 capacitor Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000012432 intermediate storage Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 208000014221 sudden cardiac arrest Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 208000003663 ventricular fibrillation Diseases 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021138 Hypovolaemic shock Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010047284 Ventricular asystole Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000011316 hemodynamic instability Diseases 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body
- A61B5/0535—Impedance plethysmography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/026—Measuring blood flow
- A61B5/0295—Measuring blood flow using plethysmography, i.e. measuring the variations in the volume of a body part as modified by the circulation of blood therethrough, e.g. impedance plethysmography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/024—Measuring pulse rate or heart rate
- A61B5/0245—Measuring pulse rate or heart rate by using sensing means generating electric signals, i.e. ECG signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/026—Measuring blood flow
- A61B5/029—Measuring blood output from the heart, e.g. minute volume
Definitions
- the present invention in some embodiments thereof, relates to cardiovascular medical applications and, more particularly, but not exclusively, to a method, apparatus and system for predicting electro-mechanical dissociation or pulseless electrical activity. Sudden cardiac arrest is a life-threatening condition. It is recognized that the percentage of individuals who are successfully resuscitated with intact neurological function following a sudden cardiac arrest is less than 10 %.
- a cardiac arrest is the cessation of normal circulation of the blood due to failure of the ventricles of the heart to contract effectively resulting in the cessation of blood delivery to the whole body.
- hypoxia oxygen starvation
- Lack of oxygen supply to the brain causes victims to immediately lose consciousness and shortly thereafter stop breathing.
- Cardiac arrest is different from a heart attack (myocardial infarction).
- heart attack myocardial infarction
- blood flow to a region of the heart muscle is disrupted. That region of the heart muscle deprived of blood flow suffers injury which might lead to cell death if blood flow is not restored promptly.
- heart attacks can sometimes lead to cardiac arrest in which the heart as a whole stops beating and ceases to promote blood flow into the systemic circulation.
- cardiac arrest is often precipitated by ventricular fibrillation, which is most often associated with underlying coronary artery disease, but may also be associated with electrical abnormalities of the heart muscle originating in a region of the heart in which there is reduction of blood flow or disproportionate increase in oxygen demands in such region.
- Cardiac arrest can also occur without ventricular fibrillation.
- the heart can stop beating because of asystole in which there are no electrical impulses originating from the heart, or because of Electromechanical Dissociation (EMD) which is a clinical condition with no palpable pulse or blood flow although coordinated ventricular electrical activity exists.
- EMD Electromechanical Dissociation
- PDA Pulseless Electrical Activity
- EMD electrospray
- a severe systemic condition which affects the heart as a component of multi organ failure.
- EMD may occur in patients with severe septic syndrome, severe hemodynamic instability such as hypovolemic shock, severe metabolic acidosis, severe hypoglycemia, disseminated cancer and so on.
- heart's muscle cells e.g., myocardium
- myocardium e.g., myocardium
- EMD occurs following treatment with a defibrillator, where a patient may exhibit an electrical pulse but not a physical pulse. It has been reported that less than 10 % of individuals with post-shock EMD survive.
- Cardiac arrest caused by asystole or pulseless electrical activity can also occur associated with existing cardiac disease, especially when severe heart failure has developed.
- U.S. Patent No. 6,440,082 to Joo et al. discloses a technique in which phonocardiogram (PCG) data electrocardiogram (ECG) data are analyzed for determining the presence of a pulse in the patient and determining whether the patient is in a state of PEA.
- the PCG data are evaluated to indicate the presence of a heart sound
- the ECG data are evaluated to indicate the presence of a QRS complex. If the time at which the QRS complex occurs is within an expected time of when the heart sound appeared to occur, a cardiac pulse is determined to be present in the patient.
- Joo et al. also disclose a technique in which the ECG data are evaluated to gate the heart sound detection process. Specifically, Joo et al. teach that if a heart sound is not detected following an R- wave, the patient may be in a state of PEA.
- U.S. Published Application No. 20030109790 to Stickney et al. discloses a technique in which PEA is detected when a patient is determined pulseless and the patient is not experiencing ventricular defibrillation, ventricular tachycardia or asystole.
- the presence or absence of a cardiac pulse is determined by evaluating fluctuations in an electrical signal that represents a measurement of the patient's transthoracic impedance; the presence or absence of ventricular defibrillation or tachycardia is determined by differentiating shockable from non-shockable cardiac rhythms according to the teachings of U.S. Patent No. 4,610,254; and the presence or absence of is determined according to the teachings of U.S. Patent No. 6,304,773.
- Stickney et al. also teach detection of PEA using ECG data wherein a state of PEA is detected when QRS complexes are repeatedly observed without detection of a cardiac pulse associated therewith.
- Some embodiments of the present invention predict onset of electromechanical dissociation in a heart of a subject using a composite input electrical signal received from the subject.
- An electrocardiac signal and a radiofrequency signal are extracted from the composite signal.
- the electrical activity of the heart is determined.
- the radiofrequency signal one or more blood flow measures are determined.
- Onset of electromechanical dissociation (EMD) or pulseless electrical activity (PEA) is predicted according to predetermined criteria which depend on the electrical activity and blood flow measure(s).
- some embodiments of the present invention predicts the onset of electromechanical dissociation ahead of time. This can be achieved by a judicious selection of the criteria for the prediction. Specifically, according to the present embodiments, impending onset of electromechanical dissociation is likely to occur, if the flow rate characterizing the mechanical activity of the heart is markedly reduced, while the rhythm characterizing the electrical activity of the heart remains above another predetermined threshold.
- a method of predicting onset of electromechanical dissociation in a heart of a subject comprises: extracting from the composite input signal an electrocardiac signal and determining electrical activity of the heart based on the electrocardiac signal; extracting from the composite input signal a radiofrequency signal and determining blood flow measure based on the radiofrequency signal; and if the blood flow measure is below a predetermined threshold and the electrical activity is above a predetermined threshold, then predicting the onset of electromechanical dissociation.
- the method can also identify electromechanical dissociation which is already in effect when there is no or minimal blood flow.
- the method determines that the blood flow measure is below the predetermined threshold, it can further compare the blood flow measure to an additional, lower, threshold. If the blood flow measure is even below the additional threshold, the method can identify that electromechanical dissociation is already in effect and, e.g., generates an alarm signal.
- a method of predicting onset of electromechanical dissociation in a heart of a subject comprises transmitting output radiofrequency signals to the subject, receiving a composite input electrical signal from the subject, and executing the method described above.
- the method further comprises reducing or eliminating amplitude modulation of the radiofrequency component so as to provide a signal of substantially constant envelope.
- the method further comprises filtering the radiofrequency signal using a dynamically variable filter.
- apparatus for predicting onset of electromechanical dissociation in a heart of a subject.
- the apparatus comprises: an input unit for receiving a composite input electrical signal from the subject; an electrocardiac unit for extracting from the composite input signal an electrocardiac signal and determining electrical activity of the heart based on the electrocardiac signal; a radiofrequency unit for extracting a radiofrequency signal from the composite input signal and determining blood flow measure based on the radiofrequency signal.
- the apparatus also comprises an output unit for outputting a signal predicting the onset of electromechanical dissociation if the blood flow measure is below a predetermined threshold and the electrical and activity is above a predetermined threshold.
- a system for predicting onset of electromechanical dissociation in a heart of a subject comprises a radiofrequency generator for generating output radiofrequency signals, a plurality of electrodes designed for transmitting the output radiofrequency signals to the subject and for sensing a composite input electrical signal from the subject, and the apparatus described above.
- the apparatus further comprises an envelope elimination unit designed and configured for reducing or eliminating amplitude modulation of the radiofrequency signal so as to provide a radiofrequency signal of substantially constant envelope.
- the apparatus further comprises a filtering unit configured for filtering the radiofrequency signal using dynamically variable filter.
- the dynamically variable filter is adapted in response to a change in a physiological condition of the subject.
- the physiological condition is a heart rate of the subject.
- a lower frequency bound characterizing the filter is about 0.9*(HR/60) Hz at all times, wherein the HR is the heart rate in units of beats per minute.
- an upper frequency bound characterizing the filter is about 6 + 1.5*[(HR/60) - 1] Hz at all times, wherein the HR is the heart rate in units of beats per minute.
- the electrocardiac signal comprises an ECG signal.
- the determination of the electrical activity comprises determination of a QRS rate from the ECG signal.
- the blood flow measure comprises cardiac output.
- the onset of electromechanical dissociation is predicted if the cardiac output is reduced by at least 50 % over a period of about five minutes and the electrical activity is characterized by a pulse rate of at least 40 pulses per minute.
- the onset of electromechanical dissociation is predicted if the cardiac output is less than 1 liter per minute over a period of about five minutes and the electrical activity is characterized by a rhythm of at least 40 cycles per minute.
- the blood flow measure comprises cardiac index.
- the onset of electromechanical dissociation is predicted if the cardiac index over a period of about five minutes is less than 1 more preferably less than 0.75 liter per minute per square meter and the electrical activity is characterized by a rhythm of at least 40 cycles per minute.
- a data processor such as a computing platform for executing a plurality of instructions.
- the data processor includes a volatile memory for storing instructions and/or data and/or a non-volatile storage, for example, a magnetic hard-disk and/or removable media, for storing instructions and/or data.
- a network connection is provided as well.
- a display and/or a user input device such as a keyboard or mouse are optionally provided as well.
- FIGs. la-b are flowchart diagrams illustrating a method suitable for predicting onset of electromechanical dissociation in a heart of a subject, according to various exemplary embodiments of the present invention
- FIG. 2 is a flowchart diagram illustrating a more detailed method suitable for predicting onset of electromechanical dissociation in a heart of a subject, according to various exemplary embodiments of the present invention
- FIG. 3 is a flowchart diagram illustrating a procedure suitable for determining mechanical activity of the heart using a radiofrequency signal according to some embodiments of the present invention
- FIGs. 4a-b show a representative example of dynamically varying frequency bounds, employed according to some embodiments of the present invention.
- FIG. 4c show a representative example of a dynamically varying frequency band, employed according to some embodiments of the present invention.
- FIG. 5 is a schematic illustration of apparatus for predicting onset of electromechanical dissociation in a heart of a subject, according to various exemplary embodiments of the present invention
- FIG. 6 is a schematic illustration of an RF processing unit, according to various exemplary embodiments of the present invention
- FIG. 7 is a block diagram of electronic circuitry according to various exemplary embodiments of the present invention.
- FIG. 8 is a schematic illustration of a system for predicting onset of electromechanical dissociation in a heart of a subject, according to a preferred embodiment of the present invention.
- the present invention in some embodiments thereof, relates to cardiovascular medical applications and, more particularly, but not exclusively, to a method, apparatus and system for predicting electro-mechanical dissociation.
- Computer programs implementing the method according to embodiments of the present invention can commonly be distributed to users on a distribution medium such as, but not limited to, a floppy disk, CD-ROM and flash memory cards. From the distribution medium, the computer programs can be copied to a hard disk or a similar intermediate storage medium. The computer programs can be run by loading the computer instructions either from their distribution medium or their intermediate storage medium into the execution memory of the computer, configuring the computer to act in accordance with the method of this invention. All these operations are well-known to those skilled in the art of computer systems.
- the method, apparatus and system of the present embodiments are particularly useful for predicting a possibility of a future onset of electromechanical dissociation in the heart of a subject. Yet, the use of the present embodiments in other situations, such as the identification of electromechanical dissociation onset, is not excluded from the scope of the present invention.
- the present embodiments predict electromechanical dissociation onset by providing a quantitative estimate of the mechanical activity of the heart while monitoring its electrical activity. Specifically, according to the present embodiments onset of electromechanical dissociation is likely to occur, if the flow rate characterizing the mechanical activity of the heart is lower then one predetermined threshold while the rhythm characterizing the electrical activity of the heart remains above another predetermined threshold.
- Figure Ia is a flowchart diagram illustrating a method suitable for predicting onset of electromechanical dissociation in a heart of a subject, according to various exemplary embodiments of the present invention.
- the method of the present embodiments uses a composite input electrical signal received from the subject.
- the composite input electrical signal typically includes a radiofrequency signal pertaining to the blood flow in the heart, and an electrocardiac signal pertaining to electrical activity in the myocardium.
- the electrocardiac signal can be an electrocardiogram (ECG) signal or a signal which correlates with an ECG signal.
- ECG electrocardiogram
- the electrocardiac signal comprises a DC signal or a signal characterized by very low frequency (less than 150 Hz).
- ECG signals for example, are typically characterized by amplitudes of 0.1-5 mV and frequencies of 0.05-130 Hz.
- the extraction of DC signal or a very low frequency signal can be done using a suitable electronic circuitry or device which receives the composite signal and filter out high frequency (typically radiofrequency) components.
- a suitable electronic circuitry or device which receives the composite signal and filter out high frequency (typically radiofrequency) components.
- Such electronic circuitries are known in the art.
- a feedback capacitor or an integrator type electronic circuitry can be constituted to extract the electrocardiac signal.
- the electronic circuitry can amplify the electrocardiac signal as known in the art.
- the radiofrequency signal is extracted from the composite input signal.
- the extraction of the radiofrequency component from the composite input signal can be done using a suitable electronic circuitry or device which receives the composite signal and filter out low frequency components.
- a suitable electronic circuitry or device which receives the composite signal and filter out low frequency components.
- Such electronic circuitries are known in the art.
- a serial capacitor or a differentiator type electronic circuitry can be constituted to extract radiofrequency signal.
- the electronic circuitry amplifies the radiofrequency signal as known in the art.
- Method steps 11 and 13 can be performed in any order of execution. In various exemplary embodiments of the invention method steps 11 and 13 are executed simultaneously.
- the method determines the electrical activity of the heart based on the electrocardiac signal.
- the method attempts to identify one or more repetitive patterns in the electrocardiac signal and determines the repetition rate of the identified patterns.
- the electrocardiac signal is an ECG signal
- the method can identify the QRS complex in the ECG signal and determine the QRS rate (e.g. , by measuring the RR interval and defining the rate as the inverse of the RR interval).
- the method determines the mechanical activity of the heart based on the radiofrequency signal.
- the mechanical activity is preferably expressed in terms of one or more blood flow measures, such as, but not limited to, cardiac output, cardiac index, stroke volume and the like.
- the determination of blood flow measure from the obtained radiofrequency signal can be done using any procedure known in the art.
- Method steps 12 and 14 can be performed in any order of execution. In various exemplary embodiments of the invention method steps 12 and 14 are executed simultaneously. At 15 the method predicts the onset of electromechanical dissociation (EMD) or
- Pulseless Electrical Activity (PEA) according to predetermined criteria.
- the criteria are preferably based on the electrical and mechanical activities as determined at 12 and 14. Generally, when the electrical activity is normal and the mechanical activity is below normal (taking into account to the age, size, weight and gender of the subject), the method predicts onset of EMD or PEA.
- FIG. Ib A representative example of a set of criteria suitable for step 15 is illustrated in Figure Ib.
- the method determines, over a predetermined period of time, whether or not the heart rate, as determined from the electrocardiac signal (see block 12 in Figure Ia), is normal. This can be done by comparing the measured rate to a predetermined threshold.
- the threshold can be about 40 beats per minute, in which case any heart rate above 40 beats per minute can be defined as "normal” and any heart rate below 40 beats per minute can be defined as "below normal.”
- the threshold can also be higher than 40 beats per minute.
- the threshold is from about 40 beats per minute to about 60 beats per minute. As used herein the term "about” refers to ⁇ 10 %. If the heart rate is below normal, the method identifies cardiac arrest (block 20) and preferably generates a cardiac arrest warning signal (not shown in Figure Ib).
- the method determines, over the predetermined time period, whether or not the blood flow measure, as determined from the radiofrequency signal (see block 14 in Figure Ia), is normal. This can be done by comparing the calculated blood flow measure to a predetermined threshold, which can be expressed either in absolute value or as a percentage of the characteristic blood flow of the subject.
- a predetermined threshold can be about X liters per minute, where X is a number ranging from about 1 to about 1.5.
- any cardiac output less than X is defined as "below normal”.
- the method can define a baseline cardiac output for the subject and compare the instantaneous cardiac output to the baseline. In this embodiment, the cardiac output can be defined as "below normal” whenever it drops below 70 % or 60 % or 50 % of the baseline.
- the predetermined threshold can be about Y liters per minute per square meter, where Y is a number ranging from about 0.75 to about 1.
- any cardiac index below Y is defined as "below normal”.
- the method can define a baseline cardiac index for the subject and compare the instantaneous cardiac index to the baseline, wherein the cardiac index can be defined as "below normal” whenever it drops below 70 % or 60 % or 50 % of the baseline.
- the method determines that the likelihood for future occurrence of EMD is high (block 19).
- the method can also provides a quantified estimate of the likelihood ⁇ e.g., expressed as percentage), for example, based on the difference between the calculated blood flow and the characteristic blood flow of the subject. If the blood flow is normal (above the predetermined threshold) the method determines that the likelihood for future occurrence of EMD is low (block 21).
- the predetermined time period over which the method compares the heart rate and blood flow measure to the thresholds is typically, but not obligatorily about five minutes.
- the comparison over this time period can be performed in continuous manner and a statistical procedure, such as a significance test can be employed during this period.
- the method can employ averaging procedure to determine an average blood flow measure and an average heart rate, and compare the averaged quantities to the respective thresholds.
- the above procedure is preferably a continuous procedure wherein the method loops back and continuously extracts the electrocardiac and radiofrequency signals as shown in Figure Ia, until a stop signal is received or until the composite input signal no longer exists.
- the method ends at step 16.
- the method begins at step 22 and optionally continues to step 23 in which output radiofrequency signals are transmitted to the subject, and step 24 in which an input composite signal is received from the subject.
- the output radiofrequency signals can be generated by a radiofrequency generator which generates a periodic high frequency current output in response to a periodic control input signal.
- the current output can be transmitted to the subject via an arrangement of electrodes for carrying current output from the radiofrequency generator as known in the art.
- the electrodes can be connected to locations of the body of the subject, e.g. , above and below the heart.
- Radiofrequency generator Current, generated by the radiofrequency generator, flows across the thorax and causes a voltage drop due to the impedance of the body.
- action potentials originated from the sinoatrial node of the heart generate electrocardiac current which propagates along the myocardium.
- the electrodes sense a composite input signal which includes both the radio frequency signal resulting from the flow of radiofrequency current across the thorax and the electrocardiac signal resulting from action potentials of the sinoatrial node.
- the method continues to steps 11, 12, 13 and 14 in which the electrocardiac and radiofrequency signals are extracted and the electrical and mechanical activities of the heart are determined as further detailed hereinabove.
- the method continues to step 15 in which the method predicts EMD onset as further detailed hereinabove.
- the method determines that EMD onset is likely to occur, the method preferably generates a warning signal (block 25), which can be accompanied by an alarm signal (audio and/or visual) sensible by the subject or others.
- the method can loop back to step 23 for continuous transmission of output radiofrequency signals and monitoring of electrical and mechanical activity of the heart.
- the method ends at step 26.
- Figure 3 is a flowchart diagram illustrating a procedure suitable for determining the mechanical activity using the radiofrequency signal which is extracted from the input composite signal according to some embodiments of the present invention.
- the procedure can be used for executing block 14 of the method described above.
- the procedure uses the radiofrequency signal as extracted in step 13 of the method.
- the extracted radiofrequency signal relates to the hemodynamic reactance of the subject's thorax.
- hemodynamic reactance refers to the imaginary part of the impedance. Techniques for extracting the imaginary part from the total impedance are known in the art. Typically, such extraction is performed at hardware level but the use of algorithm at a software level is not excluded from the scope of the present invention.
- the procedure reduces or, more preferably eliminates amplitude modulation of the extracted radiofrequency signals (block 27).
- the phase modulation of the signals is maintained.
- the extracted radiofrequency signals typically carry a substantial amount of AM noise, which can be described, without limitation as a signal v(t)cos( ⁇ t+ ⁇ (t)), which contains both phase and amplitude modulation.
- the method generates signals having a substantial constant envelope, e.g., vocos( ⁇ t+ ⁇ (t)), where v 0 is substantially a constant.
- the obtained signals thus represent the phase (or frequency) modulation of the extracted radiofrequency signal.
- the reduction or elimination of the amplitude modulation can be achieved, for example, using a limiter amplifier which amplifies the radiofrequency signals and limits their amplitude such that the amplitude modulation is removed.
- the procedure proceeds to step 28 in which the output radiofrequency signals are mixed with the extracted radiofrequency signals so as to provide a mixed radiofrequency signal.
- the mixed radiofrequency signal is composed of a plurality of radiofrequency signals, which may be, in one embodiment, a radiofrequency sum and a radiofrequency difference. A sum and a difference may be achieved, e.g., by multiplying the input and output signals. Since a multiplication between two frequencies is equivalent to a frequency sum and a frequency difference, the mix signal is composed of the desired radiofrequency sum and radiofrequency difference.
- the advantage in the production of a radiofrequency sum and a radiofrequency difference is that whereas the radiofrequency sum includes both the signal and a considerable amount of electrical noise, the radiofrequency difference is approximately noise-free.
- the procedure continues to step 30 in which a portion of the mixed signal is filtered out such that a remaining portion of the mixed signal is characterized by a signal-to-noise ratio (SNR) which is substantially higher compared to the signal-to-noise ratio of the mixed signal or the extracted radiofrequency signal.
- SNR signal-to-noise ratio
- the procedure optionally and preferably continues to step 32 in which a phase shift A ⁇ of the extracted radiofrequency signals relative to the output radiofrequency signals is determined. It was found by the inventors of the present invention that the phase shift of the input signals, as received from the subject, relative to the output signals as generated by the radiofrequency generator, is indicative of the cardiac output of the subject.
- the advantage of using A ⁇ for determining the cardiac output is that the relation between the blood flow and A ⁇ depends on fewer measurement-dependent quantities as compared to conventional determination techniques in which the impedance is used.
- the phase shift can be determined for any frequency component of the spectrum of extracted radiofrequency signals. For example, in one embodiment, the phase shift is determined from the base frequency component, in another embodiment the phase shift is determined from the second frequency component, and so on. Alternatively the phase shift can be determined using several frequency components, e.g., using an appropriate averaging algorithm.
- step 34 in which a dynamically variable filter is applied.
- the dynamically variable filter filters the data according to a frequency band which is dynamically adapted in response to a change in the physiological condition of the subject. It was found by the Inventor of the present invention that the dynamical adaptation of the frequency band to the physiological condition of the subject can significantly reduce the influence of unrelated signals on the measured property.
- step 34 includes a process in which first the physiological condition of the subject is determined, then a frequency band is selected based on the physiological condition of the subject, and thereafter the input signals or a portion thereof are filtered according to frequency band.
- the frequency band is dynamically adapted in response to a change in the physiological condition.
- the physiological condition is preferably, but not obligatorily, the heart rate of the subject, which can be determined, e.g., by analysis of the extracted electrocardiac signal.
- physiological condition which is a heart rate
- the physiological condition is a ventilation rate of the subject, a repetition rate of a particular muscle unit and/or one or more characteristics of an action potential sensed electromyography.
- the adaptation of the frequency band to the physiological condition can be according to any adaptation scheme known in the art.
- one or more parameters of the frequency band e.g., lower bound, upper bound, bandwidth, central frequency
- a parameter characterizing the physiological condition e.g., the number of heart beats per minute.
- FIG. 4a-b A representative example of a dynamically varying frequency bounds is illustrated in Figures 4a-b. Shown in Figures 4a-b is the functional dependence of the frequency bounds (upper bound in Figure 4a and lower bound in Figure 4b) on the heart rate of the subject. As shown in Figure 4a, the upper bound of the frequency band varies linearly such that at a heart rate of about 60 beats per minute (bpm) the upper bound is about 6 Hz, and at a heart rate of about 180 bpm the upper bound is about 9 Hz. Preferably, the upper bound is about 6 + 1.5 x [(HR/60) - I]Hz at all times, where HR is the heart rate of the subject in units of bpm.
- HR is the heart rate of the subject in units of bpm.
- the lower bound of the frequency band varies linearly such that at a heart rate of about 60 the lower bound is about 0.9 Hz bpm and at a heart rate of about 180 bpm the lower bound is about 2.7 Hz.
- the lower bound is about 0.9 x (HR/60) Hz at all times.
- FIG. 4c A dynamically varying band pass filter (BPF) characterized by the frequency bounds described above is illustrated in Figure 4c. As shown, each heart rate is associated with a frequency band defined by a lower bound and an upper bound. For example, for a heart rate of 60 bpm, Figure 4c depicts a BPF in which the lower bound is about 0.9 Hz and the upper bound is about 6 Hz.
- step 36 the cardiac output is calculated, based on A ⁇ . It was found by the inventor of the present invention that there is a linear relationship between A ⁇ and the cardiac output, with a proportion coefficient comprising the systolic ejection time, T.
- Step 36 can also be modified such that the stroke volume is calculated instead of the cardiac output.
- the calculated cardiac output can be used as a blood flow measure for predicting EMD onset as described above.
- the procedure continues to step 38 in which the cardiac index of the subject is calculated by dividing the cardiac output by the estimated body surface area of the subject.
- Apparatus 400 generally comprises an input unit 142, an electrocardiac unit 402 and a radiofrequency unit 404.
- Electrocardiac unit 402 preferably comprises an electrocardiac signal extractor, which extracts an electrocardiac signal 408 from composite signal 126, and an electrocardiac signal processing unit 410 which processes signal 408 and determines the electrical activity of the heart based on signal 408.
- Radiofrequency unit 404 preferably comprises an RF signal extractor, which extracts an RF signal 412 from composite signal 126, and an RF signal processing unit 44 which processes signal 412.
- the extracted radiofrequency signal 412 typically comprises radiofrequency signals related to the electrical properties of the organ (e.g., bioimpedance which may generally relate to the impedance and/or hemodynamic reactance of the organ).
- the composite signal 126 is sensed from one or more sensing locations 48 on the organ of subject 121 and is originated by output radiofrequency signals 124 generated by a radiofrequency generator 122, and action potentials originated from the sinoatrial node of the heart (not shown).
- the processing of RF signal 124 may include, for example, mixing, demodulation, determination of phase shift, analog filtering, sampling and any combination thereof.
- Signal processing unit 44 may or may not be in communication with radiofrequency generator 122, as desired.
- a representative example of signal processing unit 44 is provided hereinunder with reference to Figure 6.
- Apparatus 400 is optionally and preferably designed for determining a phase shift ⁇ of the extracted RF signal 412 relative to the generated RF signal 124. This can be done using a phase shift determinator 50 (not shown, see Figure 6) which can operate according to any known technique for determining a phase shift.
- the phase shift can be determined for any frequency component of the spectrum of the extracted radiofrequency signal. For example, in one embodiment, the phase shift is determined from the base frequency component, in another embodiment the phase shift is determined from the second frequency component, and so on. Alternatively the phase shift can be determined using several frequency components, e.g., using an appropriate averaging algorithm.
- the extracted radiofrequency signals may include one or more noise components, which may be introduced into the signal due to various reasons, e.g., subject agitation or breathing.
- apparatus 400 is capable of reducing or eliminating these noise components.
- apparatus 400 further comprises a filtering unit 46 which filters the processed input signals. Unit 46 preferably performs the filtration operation in the frequency domain.
- a series of samples of the processed radiofrequency signals are transformed, e.g., by a Fast Fourier Transform (FFT), to provide a spectral decomposition of the signals in the frequency domain.
- FFT Fast Fourier Transform
- the transformation to the frequency domain can be done by a data processor 144. Algorithms for performing such transformations are known to those skilled in the art of signal processing.
- the obtained spectral decomposition of the signal is filtered by unit 46 which typically eliminates one or more of the frequencies in the spectrum, depending on the upper and lower frequency bounds of the filter employed by unit 46.
- Unit 46 preferably employs a dynamically variable filter, such as, but not limited to, the dynamically variable filer described hereinabove.
- Unit 46 can employ data processor 144 for eliminating the frequency components according to the dynamically variable frequency bounds.
- apparatus 400 comprises a cardiac output calculator 52 which calculates the cardiac output as further detailed hereinabove.
- Cardiac output calculator 52 can be associated with data processor 144.
- Data processor 144 can also be configured for calculating other quantities, e.g., cardiac index, stroke volume and/or other blood-volume related quantities.
- FIG 6 schematically illustrates RF processing unit 44, according to various exemplary embodiments of the present invention.
- Unit 44 preferably comprises a mixer 128, electrically communicating with generator 122, for mixing RF signals 124 and RF signals 412, so as to provide a mixed radiofrequency signal.
- Signals 124 and 412 may be inputted into mixer 128 through more than one channel, depending on optional analog processing procedures (e.g., amplification) which may be performed prior to the mixing.
- Mixer 128 may be any known radiofrequency mixer, such as, but not limited to, double-balanced radiofrequency mixer and unbalanced radiofrequency mixer.
- the mixed radiofrequency signal is composed of a plurality of radiofrequency signals, which may be, in one embodiment, a radiofrequency sum and a radiofrequency difference.
- a sum and a difference may be achieved, e.g., by selecting mixer 128 such that signals 124 and signals 412 are multiplied thereby. Since a multiplication between two frequencies is equivalent to a frequency sum and a frequency difference, mixer 128 outputs a signal which is composed of the desired radiofrequency sum and radiofrequency difference.
- unit 44 further comprises a phase shift determinator 50 for determining the phase shift of the extracted RF signal relative to the generated output RF signal.
- Phase shift determinator 50 can determine the phase shift according to any technique known in the art. For example, the phase shift can be determined from the radiofrequency difference outputted from mixer 128.
- processing unit 44 further comprises electronic circuitry 132, which filters out a portion of the signal such that a remaining portion of the signal is characterized by a substantially increased signal- to-noise ratio.
- Circuitry 132 is better illustrated in Figure 7.
- circuitry 132 comprises a low pass filter 134 to filter out the high frequency content of the signal.
- Low pass filter 134 is particularly useful in the embodiment in which mixer 128 outputs a sum and a difference, in which case low pass filter 134 filters out the radiofrequency sum and leaves the approximately noise-free radiofrequency difference.
- Low pass filter 134 may be designed and constructed in accordance with the radiofrequency difference of a particular system which employs apparatus 400. A judicious design of filter 134 substantially reduces the noise content of the remaining portion.
- Circuitry 132 preferably comprises an analog amplification circuit 136 for amplifying the remaining portion of the signal.
- the construction and design of analog amplification circuit 136 is not limited, provided circuit 136 is capable of amplifying the signal.
- Amplification circuits suitable for the present embodiments are found in International Patent Application, Publication Nos. WO 2004/098376 and WO 2006/087696 the contents of which are hereby incorporated by reference.
- circuitry 132 further comprises a digitizer 138 for digitizing the signal. The digitization of the signal is useful for further digital processing of the digitized signal, e.g., by a microprocessor.
- circuitry comprises a differentiator 140 (either a digital differentiator or an analog differentiator) for performing at least one time-differentiation of the measured impedance to obtain a respective derivative (e.g., a first derivative, a second derivative, etc.) of the bioimpedance or hemodynamic reactance.
- Differentiator 140 may comprise any known electronic functionality (e.g., a chip) that is capable of performing analog or digital differentiation.
- signal processing unit 44 comprises an envelope elimination unit 135 which reduces or, more preferably, eliminates amplitude modulation of signals 412.
- unit 135 maintains the phase modulation of signal 412.
- the output of unit 135 represents the phase (or frequency) modulation of signal 412, as further detailed hereinabove.
- Unit 135 can employ, for example, a limiter amplifier which amplifies signals 412 and limits their amplitude such that the amplitude modulation is removed.
- System 120 preferably comprises a radiofrequency generator 122, for generating output radiofrequency signals.
- Generator 122 may be embodied as any device capable of generating radiofrequency signals.
- System 120 further comprises a plurality of electrodes 125, which are connected to the skin of subject 121. Electrodes 125 transmit output radiofrequency signal 124, generated by generator 122 and sense composite signal 126 which includes both the RF signal resulting from the flow of RF current across the thorax and the electrocardiac signal resulting from action potentials of the sinoatrial node.
- System 120 preferably comprises any of the components of apparatus 400 described above.
- system 120 further comprises a detector 129 for detecting a voltage drop on a portion of the body of subject 121 defined by the positions of electrodes 125.
- detector 129 preferably generates signals which are indicative of impedance or reactance of the respective portion of the body.
- the stroke volume can be calculated using (dX/dt) ma ⁇ , as further detailed hereinabove. Knowing the stroke volume, the cardiac output is calculated by multiplying the stroke volume by the heart rate of the subject. More preferably, detector 129 generates signals which are indicative of a hemodynamic reactance, X.
- a portion of signal 126 can also be inputted directly to the input unit of apparatus 400, e.g., for the purpose of extracting the electrocardiac signal.
- the output radiofrequency signals are preferably from about 10 KHz to about 200 KHz in frequency and from about 1OmV to about 20OmV in magnitude; the extracted radiofrequency signals are preferably about 75 KHz in frequency and about 2OmV in magnitude; a typical impedance which can be measured by the present embodiments is from about 5 Ohms to about 75 Ohms; the resulting signal-to-noise ratio of the present embodiments is at least 4OdB; low pass filter 134 is preferably characterized by a cutoff frequency of about 35Hz and digitizer 138 preferably samples the signals at a rate of about 500-1000 samples per second.
- compositions, methods or structures may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
- the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise.
- the term “a compound” or “at least one compound” may include a plurality of compounds, including mixtures thereof.
- range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Psychiatry (AREA)
- Signal Processing (AREA)
- Cardiology (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT08738211T ATE548967T1 (en) | 2007-04-19 | 2008-04-15 | METHOD AND APPARATUS FOR PREDICTING ELECTROCHEMICAL DISSOCIATION |
US12/596,483 US8523777B2 (en) | 2007-04-19 | 2008-04-15 | Method, apparatus and system for predicting electromechanical dissociation |
EP08738211A EP2146630B1 (en) | 2007-04-19 | 2008-04-15 | Method and apparatus for predicting electromechanical dissociation |
AU2008242145A AU2008242145B2 (en) | 2007-04-19 | 2008-04-15 | Method, apparatus and system for predicting electromechanical dissociation |
CA2683684A CA2683684C (en) | 2007-04-19 | 2008-04-15 | Method, apparatus and system for predicting electromechanical dissociation |
IL201630A IL201630A (en) | 2007-04-19 | 2009-10-19 | Method, apparatus and system for predicting electromechanical dissociation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90784707P | 2007-04-19 | 2007-04-19 | |
US60/907,847 | 2007-04-19 | ||
US11/889,395 | 2007-08-13 | ||
US11/889,395 US9095271B2 (en) | 2007-08-13 | 2007-08-13 | Dynamically variable filter |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008129535A1 true WO2008129535A1 (en) | 2008-10-30 |
Family
ID=39735256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2008/000509 WO2008129535A1 (en) | 2007-04-19 | 2008-04-15 | Method, apparatus and system for predicting electromechanical dissociation |
Country Status (6)
Country | Link |
---|---|
US (1) | US8523777B2 (en) |
EP (1) | EP2146630B1 (en) |
AT (1) | ATE548967T1 (en) |
AU (1) | AU2008242145B2 (en) |
CA (1) | CA2683684C (en) |
WO (1) | WO2008129535A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013014671A1 (en) | 2011-07-25 | 2013-01-31 | Cheetah Medical, Inc. | Method and system for monitoring hemodynamics |
US8388545B2 (en) | 2005-02-15 | 2013-03-05 | Cheetah Medical, Inc. | System, method and apparatus for measuring blood flow and blood volume |
US8414498B2 (en) | 2003-05-12 | 2013-04-09 | Cheetah Medical, Inc. | System, method and apparatus for measuring blood flow and blood volume |
US8523777B2 (en) | 2007-04-19 | 2013-09-03 | Cheetah Medical, Inc. | Method, apparatus and system for predicting electromechanical dissociation |
US8764667B2 (en) | 2007-03-07 | 2014-07-01 | Cheetah Medical, Inc. | Method and system for monitoring sleep |
US8790267B2 (en) | 2007-08-13 | 2014-07-29 | Cheetah Medical, Inc. | Dynamically variable filter |
US8876725B2 (en) | 2007-02-23 | 2014-11-04 | Cheetah Medical, Inc. | Method and system for estimating exercise capacity |
WO2021003123A1 (en) | 2019-07-01 | 2021-01-07 | Baxter International Inc. | Device and method for sensing signals from a body |
WO2021003122A1 (en) | 2019-07-01 | 2021-01-07 | Baxter International Inc. | Device and method for sensing signals from a body |
US11324954B2 (en) | 2019-06-28 | 2022-05-10 | Covidien Lp | Achieving smooth breathing by modified bilateral phrenic nerve pacing |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10500405B2 (en) | 2012-09-28 | 2019-12-10 | Physio-Control, Inc. | Preventing use of sync mode during cardioversion and defibrillation |
US9981140B2 (en) | 2012-09-28 | 2018-05-29 | Physio-Control, Inc. | Defibrillator warning of sync mode setting after delivery of shock |
US9827435B2 (en) | 2012-09-28 | 2017-11-28 | Physio-Control, Inc. | Defibrillator with sync mode assisting selection of feature to lock-on |
US9981141B2 (en) | 2012-09-28 | 2018-05-29 | Physio-Control, Inc. | Intelligent sync mode for defibrillation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000066222A1 (en) * | 1999-04-30 | 2000-11-09 | Intermedics Inc. | Method and apparatus for treatment of cardiac electromechanical dissociation |
EP1247487A1 (en) * | 2001-04-03 | 2002-10-09 | Osypka Medical GmbH | Apparatus and method for determining an approximate value of the stroke volume and the cardiac output of the heart |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3340867A (en) | 1964-08-19 | 1967-09-12 | Univ Minnesota | Impedance plethysmograph |
USRE30101E (en) | 1964-08-19 | 1979-09-25 | Regents Of The University Of Minnesota | Impedance plethysmograph |
CA1021052A (en) | 1973-02-16 | 1977-11-15 | Pierre-Andre Grandchamp | Method and apparatus for the measurement of a fluid-flow velocity profile |
US3874368A (en) | 1973-04-19 | 1975-04-01 | Manfred Asrican | Impedance plethysmograph having blocking system |
US3851641A (en) | 1973-11-29 | 1974-12-03 | J Toole | Method and apparatus for determining internal impedance of animal body part |
US4094309A (en) | 1977-03-07 | 1978-06-13 | Grzenia Robert M | Medical electrode |
US4153048A (en) | 1977-09-14 | 1979-05-08 | Cleveland Clinic Foundation | Thermodilution catheter and method |
US4437469A (en) | 1980-09-29 | 1984-03-20 | Rush-Presbyterian-St. Luke's Medical Center | System for determining characteristics of blood flow |
US4450527A (en) | 1982-06-29 | 1984-05-22 | Bomed Medical Mfg. Ltd. | Noninvasive continuous cardiac output monitor |
US4537200A (en) | 1983-07-07 | 1985-08-27 | The Board Of Trustees Of The Leland Stanford Junior University | ECG enhancement by adaptive cancellation of electrosurgical interference |
US4610254A (en) | 1984-03-08 | 1986-09-09 | Physio-Control Corporation | Interactive portable defibrillator |
GB8431500D0 (en) | 1984-12-13 | 1985-01-23 | Antec Systems | Measurement of thoracic impedances |
US4781201A (en) | 1984-12-27 | 1988-11-01 | American Home Products Corporation (Del.) | Cardiovascular artifact filter |
EP0249823B1 (en) | 1986-06-16 | 1991-12-18 | Pacesetter AB | Device for the control of a heart pacer using impedance measurement at body tissues |
JP2574767B2 (en) | 1986-07-25 | 1997-01-22 | 株式会社日立製作所 | Three-dimensional moving object imaging method |
US4705049A (en) | 1986-08-04 | 1987-11-10 | John Erwin R | Intraoperative monitoring or EP evaluation system utilizing an automatic adaptive self-optimizing digital comb filter |
US4852580A (en) | 1986-09-17 | 1989-08-01 | Axiom Medical, Inc. | Catheter for measuring bioimpedance |
US4926868A (en) | 1987-04-15 | 1990-05-22 | Larsen Lawrence E | Method and apparatus for cardiac hemodynamic monitor |
US4870578A (en) | 1987-08-19 | 1989-09-26 | Bomed Medical Manufacturing, Ltd. | Diastolic clamp for bioimpedance measuring device |
US4888558A (en) | 1988-10-26 | 1989-12-19 | Hewlett-Packard Company | Phase detector for amplitude modulated radio frequency signals containing a low frequency waveform |
US5158093A (en) | 1989-04-24 | 1992-10-27 | Esar Shvartz | Universal fitness testing system |
US5058583A (en) | 1990-07-13 | 1991-10-22 | Geddes Leslie A | Multiple monopolar system and method of measuring stroke volume of the heart |
US5178154A (en) | 1990-09-18 | 1993-01-12 | Sorba Medical Systems, Inc. | Impedance cardiograph and method of operation utilizing peak aligned ensemble averaging |
US5642734A (en) | 1990-10-04 | 1997-07-01 | Microcor, Inc. | Method and apparatus for noninvasively determining hematocrit |
US5211177A (en) | 1990-12-28 | 1993-05-18 | Regents Of The University Of Minnesota | Vascular impedance measurement instrument |
US5423326A (en) | 1991-09-12 | 1995-06-13 | Drexel University | Apparatus and method for measuring cardiac output |
US5309917A (en) | 1991-09-12 | 1994-05-10 | Drexel University | System and method of impedance cardiography and heartbeat determination |
IL102300A (en) | 1992-06-24 | 1996-07-23 | N I Medical Ltd | Non-invasive system for determining of the main cardiorespiratory parameters of the human body |
US5505209A (en) | 1994-07-07 | 1996-04-09 | Reining International, Ltd. | Impedance cardiograph apparatus and method |
US5615689A (en) | 1994-12-12 | 1997-04-01 | St. Luke's-Roosevelt Hospital | Method of predicting body cell mass using bioimpedance analysis |
US5503157A (en) | 1995-03-17 | 1996-04-02 | Sramek; Bohumir | System for detection of electrical bioimpedance signals |
US5817030A (en) | 1995-04-07 | 1998-10-06 | University Of Miami | Method and apparatus for controlling a device based on spatial discrimination of skeletal myopotentials |
JP3844779B2 (en) | 1995-04-20 | 2006-11-15 | マイクロコー インコーポレイテッド | Method and apparatus for noninvasively measuring hematocrit |
NL1001282C2 (en) | 1995-09-26 | 1997-03-28 | A J Van Liebergen Holding B V | Stroke volume determination device for a human heart. |
US5685316A (en) | 1996-04-08 | 1997-11-11 | Rheo-Graphic Pte Ltd. | Non-invasive monitoring of hemodynamic parameters using impedance cardiography |
FR2755020B1 (en) | 1996-10-31 | 1999-05-28 | Benhalima Bouziane | DEVICE FOR PERFORMING TRANSOESOPHAGAL ECHOCARDIOGRAPHY AND CARDIOVERSION |
IL125932A (en) | 1997-01-03 | 2003-06-24 | Biosense Inc | Pressure sensing stent |
US6015393A (en) | 1997-03-24 | 2000-01-18 | Urometrics, Inc. | Systems and methods for monitoring and evaluating penile tumescence |
US6073039A (en) * | 1997-11-07 | 2000-06-06 | The United States Of America As Represented By The Department Of Health And Human Services | Device and method for real-time monitoring of an electrocardiogram during magnetic resonance imaging |
US6070100A (en) | 1997-12-15 | 2000-05-30 | Medtronic Inc. | Pacing system for optimizing cardiac output and determining heart condition |
US6076015A (en) | 1998-02-27 | 2000-06-13 | Cardiac Pacemakers, Inc. | Rate adaptive cardiac rhythm management device using transthoracic impedance |
US6304773B1 (en) | 1998-05-21 | 2001-10-16 | Medtronic Physio-Control Manufacturing Corp. | Automatic detection and reporting of cardiac asystole |
IL124964A (en) | 1998-06-17 | 2002-02-10 | Nimeda Ltd | Method for disclosing a physiological indication and a non-invasive diagnostic physiological monitoring system for use therewith |
US6298267B1 (en) * | 1999-04-30 | 2001-10-02 | Intermedics Inc. | Method and apparatus for treatment of cardiac electromechanical dissociation |
JP4571317B2 (en) | 1999-06-01 | 2010-10-27 | マサチューセッツ インスティテュート オブ テクノロジー | Pressureless continuous blood pressure monitoring device |
US6440082B1 (en) | 1999-09-30 | 2002-08-27 | Medtronic Physio-Control Manufacturing Corp. | Method and apparatus for using heart sounds to determine the presence of a pulse |
US20030109790A1 (en) | 2001-12-06 | 2003-06-12 | Medtronic Physio-Control Manufacturing Corp. | Pulse detection method and apparatus using patient impedance |
AUPQ420599A0 (en) | 1999-11-24 | 1999-12-16 | Duncan Campbell Patents Pty Ltd | Method and apparatus for determining cardiac output or total peripheral resistance |
US6496732B1 (en) | 2000-05-25 | 2002-12-17 | The Regents Of The University Of California | Internal cardiac output monitor |
US7228170B2 (en) | 2000-08-14 | 2007-06-05 | Renal Research Institute, Llc | Device and method for monitoring and controlling physiologic parameters of a dialysis patient using segmental bioimpedance |
US7801598B2 (en) | 2000-08-14 | 2010-09-21 | Fresenius Medical Care Holdings, Inc. | Device and method for the determination of dry weight by continuous measurement of resistance and calculation of circumference in a body segment using segmental bioimpedance analysis |
US6795732B2 (en) * | 2001-10-30 | 2004-09-21 | Medtronic, Inc. | Implantable medical device employing sonomicrometer output signals for detection and measurement of cardiac mechanical function |
US7236821B2 (en) * | 2002-02-19 | 2007-06-26 | Cardiac Pacemakers, Inc. | Chronically-implanted device for sensing and therapy |
US6783498B2 (en) | 2002-03-26 | 2004-08-31 | Vivometrics, Inc. | Method and system for extracting cardiac parameters from plethysmographic signals |
US7024244B2 (en) | 2002-04-22 | 2006-04-04 | Medtronic, Inc. | Estimation of stroke volume cardiac output using an intracardiac pressure sensor |
MXPA05003815A (en) | 2002-10-09 | 2005-07-13 | Compumedics Ltd | Method and apparatus for maintaining and monitoring sleep quality during therapeutic treatments. |
US6868346B2 (en) | 2002-11-27 | 2005-03-15 | Cardiac Pacemakers, Inc. | Minute ventilation sensor with automatic high pass filter adjustment |
GB2396426B (en) | 2002-12-21 | 2005-08-24 | Draeger Medical Ag | Artificial respiration system |
US20040215244A1 (en) * | 2003-04-23 | 2004-10-28 | Marcovecchio Alan F. | Processing pulse signal in conjunction with ECG signal to detect pulse in external defibrillation |
EP1622508B1 (en) * | 2003-05-12 | 2014-04-09 | Cheetah Medical, Inc. | System and method for measuring blood flow and blood volume |
IES20030467A2 (en) | 2003-06-24 | 2005-02-09 | Univ Dublin | Methods for detecting sleep apnea using bioimpedance measurements |
US7186220B2 (en) | 2003-07-02 | 2007-03-06 | Cardiac Pacemakers, Inc. | Implantable devices and methods using frequency-domain analysis of thoracic signal |
US20050124901A1 (en) | 2003-12-05 | 2005-06-09 | Misczynski Dale J. | Method and apparatus for electrophysiological and hemodynamic real-time assessment of cardiovascular fitness of a user |
CA2555807A1 (en) | 2004-02-12 | 2005-08-25 | Biopeak Corporation | Non-invasive method and apparatus for determining a physiological parameter |
US20060085048A1 (en) | 2004-10-20 | 2006-04-20 | Nervonix, Inc. | Algorithms for an active electrode, bioimpedance-based tissue discrimination system |
AU2006215274B2 (en) | 2005-02-15 | 2011-12-22 | Cheetah Medical, Inc. | System, method and apparatus for measuring blood flow and blood volume |
US7668579B2 (en) | 2006-02-10 | 2010-02-23 | Lynn Lawrence A | System and method for the detection of physiologic response to stimulation |
DE102006022055A1 (en) | 2006-02-20 | 2007-08-30 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Adaptive filtering for more reliable determination of vital parameters |
US20080154116A1 (en) * | 2006-12-22 | 2008-06-26 | Duensing G Randy | Method and apparatus for obtaining electrocardiogram (ECG) signals |
US9095271B2 (en) | 2007-08-13 | 2015-08-04 | Cheetah Medical, Inc. | Dynamically variable filter |
DK2112904T3 (en) | 2007-02-23 | 2015-06-22 | Cheetah Medical Inc | PROCEDURE AND SYSTEM FOR ESTIMATING MOTION CAPACITY |
US8764667B2 (en) | 2007-03-07 | 2014-07-01 | Cheetah Medical, Inc. | Method and system for monitoring sleep |
US20080255433A1 (en) | 2007-04-11 | 2008-10-16 | The Board Of Regents Of The University Of Texas Syatem | Optoacoustic monitoring of multiple parameters |
CA2683684C (en) | 2007-04-19 | 2016-02-02 | Cheetah Medical Ltd. | Method, apparatus and system for predicting electromechanical dissociation |
USD625823S1 (en) | 2007-08-30 | 2010-10-19 | Cheetah Medical Ltd. | Electrode |
-
2008
- 2008-04-15 CA CA2683684A patent/CA2683684C/en active Active
- 2008-04-15 WO PCT/IL2008/000509 patent/WO2008129535A1/en active Application Filing
- 2008-04-15 EP EP08738211A patent/EP2146630B1/en active Active
- 2008-04-15 AU AU2008242145A patent/AU2008242145B2/en active Active
- 2008-04-15 US US12/596,483 patent/US8523777B2/en active Active
- 2008-04-15 AT AT08738211T patent/ATE548967T1/en active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000066222A1 (en) * | 1999-04-30 | 2000-11-09 | Intermedics Inc. | Method and apparatus for treatment of cardiac electromechanical dissociation |
EP1247487A1 (en) * | 2001-04-03 | 2002-10-09 | Osypka Medical GmbH | Apparatus and method for determining an approximate value of the stroke volume and the cardiac output of the heart |
Non-Patent Citations (2)
Title |
---|
TCHOUDOVSKI ET AL., CONF PROC IEEE ENG MED BIOL SOC., vol. 2, 2004, pages 956 - 9 |
TCHOUDOVSKI I ET AL: "New approach in developing of the algorithms for resuscitation assistance", CONFERENCE PROCEEDINGS. 26TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (IEEE CAT. NO.04CH37558) IEEE PISCATAWAY, NJ, USA, vol. 2, 2004, pages 956 - 959 Vol.2, XP002495751, ISBN: 0-7803-8439-3 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8414498B2 (en) | 2003-05-12 | 2013-04-09 | Cheetah Medical, Inc. | System, method and apparatus for measuring blood flow and blood volume |
US10617322B2 (en) | 2005-02-15 | 2020-04-14 | Cheetah Medical, Inc. | System, method and apparatus for measuring blood flow and blood volume |
US8388545B2 (en) | 2005-02-15 | 2013-03-05 | Cheetah Medical, Inc. | System, method and apparatus for measuring blood flow and blood volume |
US8876725B2 (en) | 2007-02-23 | 2014-11-04 | Cheetah Medical, Inc. | Method and system for estimating exercise capacity |
US8764667B2 (en) | 2007-03-07 | 2014-07-01 | Cheetah Medical, Inc. | Method and system for monitoring sleep |
US8523777B2 (en) | 2007-04-19 | 2013-09-03 | Cheetah Medical, Inc. | Method, apparatus and system for predicting electromechanical dissociation |
US8790267B2 (en) | 2007-08-13 | 2014-07-29 | Cheetah Medical, Inc. | Dynamically variable filter |
US9095271B2 (en) | 2007-08-13 | 2015-08-04 | Cheetah Medical, Inc. | Dynamically variable filter |
US10842386B2 (en) | 2007-08-13 | 2020-11-24 | Baxter International Inc. | Dynamically variable filter |
US10448841B2 (en) | 2011-07-25 | 2019-10-22 | Cheetah Medical, Inc. | Method and system for monitoring hemodynamics |
WO2013014671A1 (en) | 2011-07-25 | 2013-01-31 | Cheetah Medical, Inc. | Method and system for monitoring hemodynamics |
US10456047B2 (en) | 2011-07-25 | 2019-10-29 | Cheetah Medical, Inc. | Method and system for monitoring hemodynamics |
US10512405B2 (en) | 2011-07-25 | 2019-12-24 | Cheetah Medical, Inc. | Method and system for monitoring hemodynamics |
US10433735B2 (en) | 2011-07-25 | 2019-10-08 | Cheetah Medical, Inc. | Method and system for monitoring hemodynamics |
US9380947B2 (en) | 2011-07-25 | 2016-07-05 | Cheetah Medical, Inc. | Method and system for monitoring hemodynamics |
US11389070B2 (en) | 2011-07-25 | 2022-07-19 | Baxter International Inc. | Method and system for monitoring hemodynamics |
EP4309576A2 (en) | 2011-07-25 | 2024-01-24 | Cheetah Medical, Inc. | Method and system for monitoring hemodynamics |
US11324954B2 (en) | 2019-06-28 | 2022-05-10 | Covidien Lp | Achieving smooth breathing by modified bilateral phrenic nerve pacing |
US12036409B2 (en) | 2019-06-28 | 2024-07-16 | Covidien Lp | Achieving smooth breathing by modified bilateral phrenic nerve pacing |
WO2021003123A1 (en) | 2019-07-01 | 2021-01-07 | Baxter International Inc. | Device and method for sensing signals from a body |
WO2021003122A1 (en) | 2019-07-01 | 2021-01-07 | Baxter International Inc. | Device and method for sensing signals from a body |
Also Published As
Publication number | Publication date |
---|---|
EP2146630A1 (en) | 2010-01-27 |
AU2008242145A1 (en) | 2008-10-30 |
AU2008242145B2 (en) | 2013-05-02 |
ATE548967T1 (en) | 2012-03-15 |
CA2683684A1 (en) | 2008-10-30 |
CA2683684C (en) | 2016-02-02 |
US8523777B2 (en) | 2013-09-03 |
EP2146630B1 (en) | 2012-03-14 |
US20100217140A1 (en) | 2010-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2683684C (en) | Method, apparatus and system for predicting electromechanical dissociation | |
AU2018250405B2 (en) | Method and system for monitoring hemodynamics | |
CA2695726C (en) | Dynamically variable filter | |
Cain et al. | Fast-Fourier transform analysis of signal-averaged electrocardiograms for identification of patients prone to sustained ventricular tachycardia. | |
US9706952B2 (en) | System for ventricular arrhythmia detection and characterization | |
US8764667B2 (en) | Method and system for monitoring sleep | |
US20050245973A1 (en) | Methods and devices to characterize the probability of successful defibrillation and determine treatments for ventricular fibrillation | |
EP2112904B1 (en) | Method and system for estimating exercise capacity | |
US8457724B2 (en) | System for heart performance characterization and abnormality detection | |
US8818494B2 (en) | System for ventricular function abnormality detection and characterization | |
US8876725B2 (en) | Method and system for estimating exercise capacity | |
Postolache et al. | New insight into arrhythmia onset using HRV and BPV analysis | |
IL201630A (en) | Method, apparatus and system for predicting electromechanical dissociation | |
Rahman et al. | Respiration monitoring by using ECG | |
Besleaga et al. | Real Time Non-Invasive Hemodynamic Assessment of Ventricular Tachycardia | |
Malik et al. | Detection of heart conditions using HRV processor in Matlab simulink | |
IL203871A (en) | Dynamically variable filter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08738211 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2683684 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201630 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008738211 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008242145 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6787/CHENP/2009 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2008242145 Country of ref document: AU Date of ref document: 20080415 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12596483 Country of ref document: US |